Well-funded biotech Moderna Therapeutics has inked a long-term deal with Sweden's Karolinska Institutet to spotlight new applications for the company's messenger RNA technology.
Given the eyebrow-raising cash component in Celgene's new deal with Nogra, we thought it would be fun to list the top 10 upfronts paid for experimental drugs, ranked simply according to the cash included in the upfront--no surer sign of what a company really thinks about the potential of an experimental therapy or portfolio.
Moderna Therapeutics has chosen the big stage of the J.P. Morgan conference to unveil its next gambit: splitting in two and launching a standalone company to advance its oncology programs.
Cambridge, MA's Moderna Therapeutics is marching on with another high-dollar deal, getting $125 million up front to lend its messenger RNA platform to rare disease luminary Alexion Pharmaceuticals.
Moderna Therapeutics is having quite a year, and the Cambridge, MA, biotech just put a $110 million capstone on 2013, raising a colossal new round and riding high on technology that promises to transform the human body into a drug factory.
Moderna Therapeutics' messenger RNA therapy platform is attracting attention these days. The Cambridge, MA-based company has won a notable deal with the U.S. government--worth up to $25 million--to develop its therapeutics to make antibody-producing drugs that would combat emerging infectious diseases and biological health threats.
Our annual Fierce 15 report on a top class of up-and-coming private biotechs came out today and I wanted to highlight the responses from many of the companies which are on the list. Read more | Check out this year's report
Last year when Ryan McBride and I were sorting through our short list of candidates, we both felt that Seaside Therapeutics deserved a spot on the list. The small company had raised a considerable...
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email |...
Two years after leaving the biotech giant Genzyme, Henri Termeer has found increased demand for his expertise and personal resources from a growing crowd of startups in the Boston area and The Netherlands, he told FierceBiotech in an interview. Read more >>